Valneva announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending authorization of Valneva’s single-dose vaccine for the prevention of disease caused by the chikungunya virus in individuals 18 years of age and older.
- If approved, IXCHIQ® will become the first vaccine available in the EU against the chikungunya virus (CHIKV)
- Decision on EU marketing authorization expected in the third quarter of 2024